[{"id":"idea-chip-risk-modifiers","kind":"idea","name":"Which patients' blood clones will become leukaemia after treatment?","route":"/ideas/idea-chip-risk-modifiers/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/mechanisms.ts","type":"changed","fields":[{"field":"rationale","before":"\"Bolton 2020 fitness landscapes; growing populations on long-term PARP inhibitors and 177Lu therapies.\"","after":"\"Bolton 2020 described the fitness landscapes of these clones under therapy, and the populations on long-term PARP inhibitors and 177Lu therapies are growing.\""}]},{"id":"idea-chip-risk-modifiers","kind":"idea","name":"Which patients' blood clones will become leukaemia after treatment?","route":"/ideas/idea-chip-risk-modifiers/","commit":"a01207de6c","date":"2026-09-08","author":"Jude Gomila","message":"Mechanism research map: 31 pathway diagrams (metastasis, TME, metabolism, CIN, dormancy, MYC, Hippo, splicing…), 14 hallmark terms + core vo","file":"src/data/mechanisms.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"maturity"},{"field":"tldr"},{"field":"summary"},{"field":"hypothesis"},{"field":"rationale"},{"field":"test"},{"field":"pathways"},{"field":"targets"},{"field":"technologies"},{"field":"cancers"},{"field":"institutions"},{"field":"tags"}]}]